All models were adjusted for age, sex, educational level, and shipment
Ridker et al., 2000), where the CANTOS study, for the first time, established reduced rates of cardiovascular events following an anti-interleukin-1 beta (IL-1) based therapy, independent of cholesterol levels (Ridker et al., 2017)
Statements These statements have not been evaluated by the Food and Drug Administration
Substance-use disorders Pre-clinical and mechanistic studies A large body of pre-clinical and mechanistic literature is available regarding the putative effects of GLP-1RAs on substance misuse (Supplementary Section 5): 24 for alcohol 59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82 , 8 for opiates 63,83,84,85,86,87,88,89 , 16 for stimulants, including cocaine and amphetamines 90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105 , and 4 for nicotine 106,107,108,109